Personalized cancer vaccine plus immunotherapy reduces melanoma recurrence after surgery
Adding a personalized mRNA-based cancer vaccine to immunotherapy after surgery for high-risk melanoma reduced the risk of recurrence or death by 42%, according to results from the phase 3 INTerpath-001 trial presented at the ESMO Congress 2026. The vaccine, intismeran autogene, was given alongside pembrolizumab and compared with pembrolizumab alone.
We haven't written up this one. Medical Xpress has the full story — the link below goes straight to it.
